TY - JOUR
T1 - Novel Self-Forming Nanosized DDS Particles for BNCT
T2 - Utilizing A Hydrophobic Boron Cluster and Its Molecular Glue Effect
AU - Fithroni, Abdul Basith
AU - Kobayashi, Kazuko
AU - Uji, Hirotaka
AU - Ishimoto, Manabu
AU - Akehi, Masaru
AU - Ohtsuki, Takashi
AU - Matsuura, Eiji
N1 - Funding Information:
This study was done as a collaboration work with Fukushima SiC Applied Engineering Inc. and was partly supported by a grant from the Japan Agency for Medical Research and Development, Japan, and the Project for Cancer Research and Therapeutic Evolution (P-CREATE).
Publisher Copyright:
© 2022 by the authors.
PY - 2022/10
Y1 - 2022/10
N2 - BNCT is a non-invasive cancer therapy that allows for cancer cell death without harming adjacent cells. However, the application is limited, owing to the challenges of working with clinically approved boron (B) compounds and drug delivery systems (DDS). To address the issues, we developed self-forming nanoparticles consisting of a biodegradable polymer, namely, “AB-type Lactosome (AB-Lac)” loaded with B compounds. Three carborane isomers (o-, m-, and p-carborane) and three related alkylated derivatives, i.e., 1,2-dimethy-o-carborane (diC1-Carb), 1,2-dihexyl-o-carborane (diC6-Carb), and 1,2-didodecyl-o-carborane (diC12-Carb), were separately loaded. diC6-Carb was highly loaded with AB-Lac particles, and their stability indicated the “molecular glue” effect. The efficiency of in vitro B uptake of diC6-Carb for BNCT was confirmed at non-cytotoxic concentration in several cancer cell lines. In vivo/ex vivo biodistribution studies indicated that the AB-Lac particles were remarkably accumulated within 72 h post-injection in the tumor lesions of mice bearing syngeneic breast cancer (4T1) cells, but the maximum accumulation was reached at 12 h. In ex vivo B biodistribution, the ratios of tumor/normal tissue (T/N) and tumor/blood (T/Bl) of the diC6-Carb-loaded particles remained stably high up to 72 h. Therefore, we propose the diC6-Carb-loaded AB-Lac particles as a promising candidate medicine for BNCT.
AB - BNCT is a non-invasive cancer therapy that allows for cancer cell death without harming adjacent cells. However, the application is limited, owing to the challenges of working with clinically approved boron (B) compounds and drug delivery systems (DDS). To address the issues, we developed self-forming nanoparticles consisting of a biodegradable polymer, namely, “AB-type Lactosome (AB-Lac)” loaded with B compounds. Three carborane isomers (o-, m-, and p-carborane) and three related alkylated derivatives, i.e., 1,2-dimethy-o-carborane (diC1-Carb), 1,2-dihexyl-o-carborane (diC6-Carb), and 1,2-didodecyl-o-carborane (diC12-Carb), were separately loaded. diC6-Carb was highly loaded with AB-Lac particles, and their stability indicated the “molecular glue” effect. The efficiency of in vitro B uptake of diC6-Carb for BNCT was confirmed at non-cytotoxic concentration in several cancer cell lines. In vivo/ex vivo biodistribution studies indicated that the AB-Lac particles were remarkably accumulated within 72 h post-injection in the tumor lesions of mice bearing syngeneic breast cancer (4T1) cells, but the maximum accumulation was reached at 12 h. In ex vivo B biodistribution, the ratios of tumor/normal tissue (T/N) and tumor/blood (T/Bl) of the diC6-Carb-loaded particles remained stably high up to 72 h. Therefore, we propose the diC6-Carb-loaded AB-Lac particles as a promising candidate medicine for BNCT.
KW - biologically self-degradable amphipathic polymer (Lactosome)
KW - boron neutron capture therapy (BNCT)
KW - carborane isomers or o-carborane alkylated derivatives
KW - hydrophobic boron cluster
KW - molecular glue effect
UR - http://www.scopus.com/inward/record.url?scp=85140619617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140619617&partnerID=8YFLogxK
U2 - 10.3390/cells11203307
DO - 10.3390/cells11203307
M3 - Article
C2 - 36291173
AN - SCOPUS:85140619617
SN - 2073-4409
VL - 11
JO - Cells
JF - Cells
IS - 20
M1 - 3307
ER -